Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 7

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 7
---
” beginning on page S-6 of this prospectus supplement and incorporated by reference in this 
 prospectus supplement, including the risk factors incorporated by reference from our filings with the SEC.                                                                                       |

| Nasdaq Capital Market Symbol | “INKT” |

The number of shares of our common stock to be outstanding immediately after this offering is based on 3,965,597 shares of our common stock outstanding as of March 31, 2025 and excludes:

| • |     | 884,371 shares of common stock issuable upon exercise of the options granted to employees and non-employees, as well as options granted to members of the board of directors, at a weighted-average exercise price of $17.76 per share, as of March 31, 2025; |

| • |     | 89,676 shares of common stock issuable upon vesting of non-vested stock 
 granted to employees, consultants and directors, as of March 31, 2025;  |

S-3

| • |     | 391,178 shares of common stock reserved for issuance under our 2021 Equity Incentive Plan, as of March 31, 
 2025;                                                                                                      |

| • |     | 173,492 shares of common stock reserved for issuance under our 2021 Employee Stock Purchase Plan, as of 
 March 31, 2025; and                                                                                     |

Unless otherwise indicated, this prospectus supplement reflects and assumes no exercise of outstanding options and warrants to purchase common stock, and no issuance of shares available for future issuance under our equity compensation plans.

S-4

RISK FACTORS

Before purchasing any of the securities you should carefully consider the risk factors relating to MiNK described below and incorporated by reference in this prospectus supplement and the accompanying prospectus from our Annual Report on Form 10-Kfor the year ended December 31, 2024, our Quarterly Report on Form 10-Qfor the quarter ended March 31, 2025, as well as the risks, uncertainties and additional information set forth in our reports on Forms 10-K, 10-Qand 8-Kfiled with the SEC, and in the other documents incorporated by reference into this prospectus and the accompanying prospectus. For a description of these reports and documents, and information about where you can find them, see “Where You Can Find More Information” and “Incorporation of Certain Documents By Reference.” Additional risks not presently known or that we presently